Editorial introductions : Current Opinion in Rheumatology

Secondary Logo

Journal Logo

EDITORIAL INTRODUCTIONS

Editorial introductions

Editor(s): Varga, John; Yazici, Hasan; Yazici, Yusuf; Attur, Mukundan

Current Opinion in Rheumatology 35(1):p v-vi, January 2023. | DOI: 10.1097/BOR.0000000000000920
  • Free

Current Opinion in Rheumatology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of Rheumatology is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.

EDITOR IN CHIEF

John Varga

figure1
John Varga

Dr Varga was born in Budapest, Hungary, and came to the United States at the age of fifteen as a refugee. He matriculated at Columbia University in New York City, and obtained his medical degree from New York University. Following Rheumatology fellowship in Boston, he pursued research training with Professor Sergio Jimenez at the University of Pennsylvania. He served on the faculty at Jefferson Medical College, the University of Illinois and Feinberg School of Medicine. In 2020 he was recruited as Chief of Rheumatology at the University of Michigan Medical School. Dr Varga's research focuses on the biology and treatment of scleroderma and fibrosis, and bridges clinical and laboratory-based investigation.

Dr Varga has mentored over 20 trainees, several of whom are now independent academic investigators. He is the author of more than 400 original articles and book chapters and four books. His research has been continuously funded by the National Institutes of Health. He is an elected member of the Association of American Physicians, AOA and the Henry Kunkel Society, and is Master of the American College of Rheumatology and member of its Board of Directors.

SECTION EDITORS

Hasan Yazici

figure2
Hasan Yazici

Hasan Yazici, MD is a retired Professor of Medicine and Rheumatology. He currently practices Rheumatology, part time, at the Academic Hospital in Istanbul, Turkey. He still weekly attends the dedicated Behçet's syndrome outpatient clinic he has started with a group of his colleagues 40 years ago and co-edits the LER & CER - Letter to Editor Rheumatology: commentary and controversy in Rheumatology section in Clinical and Experimental Rheumatology.

After Dr Yazici received his MD from University of Istanbul, Turkey in 1969, he trained in internal medicine and rheumatology at the University of Nebraska and Creighton University (Metabolic Research Unit) in Omaha, Nebraska, USA, where his mentor was Paul D. Saville.

After returning to Turkey in 1974, he joined the Cerrahpasa Medical Faculty of University of Istanbul where he started both the multidisciplinary Behçet Disease Outpatient Clinic and the Division of Rheumatology, which he chaired until his retirement six years ago. His main research interests are Behçet's syndrome, clinical research methodology and ethics. He has published many original articles in peer reviewed journals in addition to his text book contributions, editorials, reviews and is the most cited author on Behçet's disease on Web of Science.

Dr Yazici has received a number of prestigious awards and has a long list of memberships in scientific societies including Science Academy Society of Turkey, European Academy of Sciences, Master of the American College of Rheumatology and the recipient of the 2012 EULAR award for Meritorious Service in Rheumatology.

Yusuf Yazici

figure3
Yusuf Yazici

Yusuf Yazici, MD, is a Clinical Associate Professor of Medicine at the New York University School of Medicine.

Dr Yazici earned his medical degree from Cerrahpasa Medical Faculty of Istanbul University in Istanbul, Turkey. He completed his internship and residency at Creighton University in Nebraska, USA and his fellowship in rheumatology at the Hospital for Special Surgery of Weill Medical College of Cornell University, USA.

His areas of interest are rheumatoid arthritis, early arthritis, patient reported outcomes, database and registry management and monitoring of arthritis patients in regard to clinical response and adverse events related to treatment and Behcet's syndrome. He has published over 200 articles and presented at various national and international meetings over 100 times.

Dr Yazici divides his time between seeing patients and conducting both industry and investigator-initiated trials, in the areas of RA and Behcet's syndrome.

Mukundan Attur

figure4
Mukundan Attur

Mukundan Attur, PhD, is Associate Professor of Medicine in the Department of Medicine, Division of Rheumatology, of NYU School of Medicine, NYU Langone Health, New York, NY. He received his PhD degree from Madurai Kamaraj University, India, and joined the NYU Division of Rheumatology. Dr Attur's interests are in the expression and role of inflammatory mediators in osteoarthritic cartilage, with the aim to elucidate the autocrine and paracrine mechanisms of action of inflammatory cytokines and lipids (eicosanoids) in chondrocytes using genomics and proteomics approaches. Dr Attur is privileged to work under the supervision of Dr Steven B. Abramson, with whom he has developed transcriptome- and protein-based biomarkers to identify subjects at risk for development of severe knee osteoarthritis. Currently, as Director of the Rheumatology Research Laboratory at NYU Langone Orthopedic Hospital, Dr Attur has established and maintained arthritis Biobank. His current research focuses on the pathophysiology, diagnosis and treatment of osteoarthritis, with special interest in extracellular non-collagenous proteins expressed in bone and cartilage. Dr Attur through proteogenomics- system biology approach has identified several genes and proteins that are examined as biomarkers to predict knee osteoarthritis development and progression. He is the author of over 77 publication and numerous invited reviews.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.